← SynDRA
MIVEBRESIB
SynDRA canonical compound SYN0038683 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | BRD4 | MYC | TMPRSS2-ERG |
|---|
| Mechanism of action | bromodomain inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- BET bromodomain inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- TSPO
- BRD2
- BRD3
- BRDT
- ADORA2B
- EP300
- CYP3A5
- TRIM33
- TRIM24
- TAF1L
- SMARCA4
- SMARCA2
- PBRM1
- KAT2B
- KAT2A
- ADORA1
- CYP3A4
- BRWD1
- BRPF3
- BRPF1
- BRD9
- BRD8
- BRD7
- BAZ2B
- BAZ2A
- CECR2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- HLAB
- IFNB1
- KSYK
- NSD2
- PARP1
- SYK
Cross-references
Synonyms
- ABBV-075
- ABBV075
- UNII-VR86R11J7J
- VR86R11J7J
- N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide
- N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide
- 8NG
- Mivebresib [INN]
- ABBV-075 (Mivebresib)
- GTPL9117
- SCHEMBL15068241
- CHEMBL3987016
- Mivebresib(ABBV-075 pound(c)
- MolPort-044-561-801
- RDONXGFGWSSFMY-UHFFFAOYSA-N
- BDBM220447
- EX-A1082
- s8400
- ZINC146486516
- AKOS030628486
- CS-5815
- ABBV 075
- mivebresibum
- RefChem:925943
- MFCD30377200
- Mivebresib [USAN]
- Mivebresib(ABBV-075
- Mivebresib (USAN/INN)
- Mivebresib [USAN:INN]
- Mivebresib(ABBV-075?
- Mivebresib; ABBV-075
- Mivebresib (ABBV-075)
- MIVEBRESIB [WHO-DD]
- orb1303860
- C22H19F2N3O4S
- SCHEMBL29362711
- SCHEMBL29430453
- GLXC-10559
- NSC793103
Look up MIVEBRESIB in the interactive SynDRA portal →